Matches in Nanopublications for { <http://www.w3.org/2000/01/rdf-schema#SENTENCE> ?p ?o ?g. }
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis" provenance.
- SENTENCE label "Notably, IL-2 plus dexamethasone combined treatment before infection was associated with increased Treg cells proliferation and expression of GATA-3, IL-4 and IL-10, and increased mice survival time." provenance.
- SENTENCE label "Notably, IL-2 plus dexamethasone combined treatment before infection was associated with increased Treg cells proliferation and expression of GATA-3, IL-4 and IL-10, and increased mice survival time." provenance.
- SENTENCE label "Notably, IL-2 plus dexamethasone combined treatment before infection was associated with increased Treg cells proliferation and expression of GATA-3, IL-4 and IL-10, and increased mice survival time." provenance.
- SENTENCE label "Notably, IL-2 plus dexamethasone combined treatment before infection was associated with increased Treg cells proliferation and expression of GATA-3, IL-4 and IL-10, and increased mice survival time." provenance.
- SENTENCE label "Notably, IL-2 plus dexamethasone combined treatment before infection was associated with increased Treg cells proliferation and expression of GATA-3, IL-4 and IL-10, and increased mice survival time." provenance.
- SENTENCE label "Notably, IL-2 plus dexamethasone combined treatment before infection was associated with increased Treg cells proliferation and expression of GATA-3, IL-4 and IL-10, and increased mice survival time." provenance.
- SENTENCE label "Notably, IL-2 plus dexamethasone combined treatment before infection was associated with increased Treg cells proliferation and expression of GATA-3, IL-4 and IL-10, and increased mice survival time." provenance.
- SENTENCE label "Notably, IL-2 plus dexamethasone combined treatment before infection was associated with increased Treg cells proliferation and expression of GATA-3, IL-4 and IL-10, and increased mice survival time." provenance.
- SENTENCE label "Notably, IL-2 plus dexamethasone combined treatment before infection was associated with increased Treg cells proliferation and expression of GATA-3, IL-4 and IL-10, and increased mice survival time." provenance.
- SENTENCE label "Notably, IL-2 plus dexamethasone combined treatment before infection was associated with increased Treg cells proliferation and expression of GATA-3, IL-4 and IL-10, and increased mice survival time." provenance.
- SENTENCE label "Notably, IL-2 plus dexamethasone combined treatment before infection was associated with increased Treg cells proliferation and expression of GATA-3, IL-4 and IL-10, and increased mice survival time." provenance.
- SENTENCE label "Notably, IL-2 plus dexamethasone combined treatment before infection was associated with increased Treg cells proliferation and expression of GATA-3, IL-4 and IL-10, and increased mice survival time." provenance.
- SENTENCE label "Notably, IL-2 plus dexamethasone combined treatment before infection was associated with increased Treg cells proliferation and expression of GATA-3, IL-4 and IL-10, and increased mice survival time." provenance.
- SENTENCE label "Notably, IL-2 plus dexamethasone combined treatment before infection was associated with increased Treg cells proliferation and expression of GATA-3, IL-4 and IL-10, and increased mice survival time." provenance.
- SENTENCE label "Notably, IL-2 plus dexamethasone combined treatment before infection was associated with increased Treg cells proliferation and expression of GATA-3, IL-4 and IL-10, and increased mice survival time." provenance.
- SENTENCE label "Notably, IL-2 plus dexamethasone combined treatment before infection was associated with increased Treg cells proliferation and expression of GATA-3, IL-4 and IL-10, and increased mice survival time." provenance.
- SENTENCE label "Notably, IL-2 plus dexamethasone combined treatment before infection was associated with increased Treg cells proliferation and expression of GATA-3, IL-4 and IL-10, and increased mice survival time." provenance.
- SENTENCE label "Notably, IL-2 plus dexamethasone combined treatment before infection was associated with increased Treg cells proliferation and expression of GATA-3, IL-4 and IL-10, and increased mice survival time." provenance.
- SENTENCE label "Notably, IL-2 plus dexamethasone combined treatment before infection was associated with increased Treg cells proliferation and expression of GATA-3, IL-4 and IL-10, and increased mice survival time." provenance.
- SENTENCE label "Notably, IL-2 plus dexamethasone combined treatment before infection was associated with increased Treg cells proliferation and expression of GATA-3, IL-4 and IL-10, and increased mice survival time." provenance.
- SENTENCE label "Notably, IL-2 plus dexamethasone combined treatment before infection was associated with increased Treg cells proliferation and expression of GATA-3, IL-4 and IL-10, and increased mice survival time." provenance.
- SENTENCE label "Notably, IL-2 plus dexamethasone combined treatment before infection was associated with increased Treg cells proliferation and expression of GATA-3, IL-4 and IL-10, and increased mice survival time." provenance.
- SENTENCE label "Notably, IL-2 plus dexamethasone combined treatment before infection was associated with increased Treg cells proliferation and expression of GATA-3, IL-4 and IL-10, and increased mice survival time." provenance.
- SENTENCE label "Notably, IL-2 plus dexamethasone combined treatment before infection was associated with increased Treg cells proliferation and expression of GATA-3, IL-4 and IL-10, and increased mice survival time." provenance.
- SENTENCE label "Notably, IL-2 plus dexamethasone combined treatment before infection was associated with increased Treg cells proliferation and expression of GATA-3, IL-4 and IL-10, and increased mice survival time." provenance.
- SENTENCE label "Notably, IL-2 plus dexamethasone combined treatment before infection was associated with increased Treg cells proliferation and expression of GATA-3, IL-4 and IL-10, and increased mice survival time." provenance.
- SENTENCE label "Notably, IL-2 plus dexamethasone combined treatment before infection was associated with increased Treg cells proliferation and expression of GATA-3, IL-4 and IL-10, and increased mice survival time." provenance.
- SENTENCE label "Notably, IL-2 plus dexamethasone combined treatment before infection was associated with increased Treg cells proliferation and expression of GATA-3, IL-4 and IL-10, and increased mice survival time." provenance.
- SENTENCE label "The utility of the '3D RNA-seq' App, an R shiny App and web-based pipeline for the comprehensive analysis of RNA-seq data from any organism is illustrated by analysis of data from a time-series of cold-treated Arabidopsis plants and from dexamethasone-treated male and female mouse cortex and hypothalamus data identifying dexamethasone-induced sex- and brain region-specific differential gene expression and alternative splicing." provenance.
- SENTENCE label "We evaluated whether etoposide + dexamethasone-based chemotherapy regimens might be useful for treating hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy." provenance.
- SENTENCE label "We evaluated whether etoposide + dexamethasone-based chemotherapy regimens might be useful for treating hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy." provenance.
- SENTENCE label "We evaluated whether etoposide + dexamethasone-based chemotherapy regimens might be useful for treating hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy." provenance.
- SENTENCE label "We evaluated whether etoposide + dexamethasone-based chemotherapy regimens might be useful for treating hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy." provenance.
- SENTENCE label "We evaluated whether etoposide + dexamethasone-based chemotherapy regimens might be useful for treating hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy." provenance.
- SENTENCE label "We evaluated whether etoposide + dexamethasone-based chemotherapy regimens might be useful for treating hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy." provenance.
- SENTENCE label "We evaluated whether etoposide + dexamethasone-based chemotherapy regimens might be useful for treating hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy." provenance.
- SENTENCE label "We evaluated whether etoposide + dexamethasone-based chemotherapy regimens might be useful for treating hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy." provenance.
- SENTENCE label "We evaluated whether etoposide + dexamethasone-based chemotherapy regimens might be useful for treating hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy." provenance.
- SENTENCE label "We evaluated whether etoposide + dexamethasone-based chemotherapy regimens might be useful for treating hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy." provenance.
- SENTENCE label "We evaluated whether etoposide + dexamethasone-based chemotherapy regimens might be useful for treating hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy." provenance.
- SENTENCE label "We evaluated whether etoposide + dexamethasone-based chemotherapy regimens might be useful for treating hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy." provenance.
- SENTENCE label "We evaluated whether etoposide + dexamethasone-based chemotherapy regimens might be useful for treating hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy." provenance.
- SENTENCE label "We evaluated whether etoposide + dexamethasone-based chemotherapy regimens might be useful for treating hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy." provenance.
- SENTENCE label "We evaluated whether etoposide + dexamethasone-based chemotherapy regimens might be useful for treating hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy." provenance.
- SENTENCE label "We evaluated whether etoposide + dexamethasone-based chemotherapy regimens might be useful for treating hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy." provenance.
- SENTENCE label "We evaluated whether etoposide + dexamethasone-based chemotherapy regimens might be useful for treating hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy." provenance.
- SENTENCE label "We evaluated whether etoposide + dexamethasone-based chemotherapy regimens might be useful for treating hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy." provenance.
- SENTENCE label "We evaluated whether etoposide + dexamethasone-based chemotherapy regimens might be useful for treating hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy." provenance.
- SENTENCE label "We evaluated whether etoposide + dexamethasone-based chemotherapy regimens might be useful for treating hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy." provenance.
- SENTENCE label "We evaluated whether etoposide + dexamethasone-based chemotherapy regimens might be useful for treating hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy." provenance.
- SENTENCE label "We evaluated whether etoposide + dexamethasone-based chemotherapy regimens might be useful for treating hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy." provenance.
- SENTENCE label "We evaluated whether etoposide + dexamethasone-based chemotherapy regimens might be useful for treating hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy." provenance.
- SENTENCE label "We evaluated whether etoposide + dexamethasone-based chemotherapy regimens might be useful for treating hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy." provenance.
- SENTENCE label "In a case of chronic active hepatitis B with COVID-19 in pregnancy, we applied liver protective and antiviral agents, and low-dose dexamethasone therapy to successfully treat the critically ill pregnant woman suffering from chronic active hepatitis B combined with COVID-19." provenance.
- SENTENCE label "In a case of chronic active hepatitis B with COVID-19 in pregnancy, we applied liver protective and antiviral agents, and low-dose dexamethasone therapy to successfully treat the critically ill pregnant woman suffering from chronic active hepatitis B combined with COVID-19." provenance.
- SENTENCE label "In a case of chronic active hepatitis B with COVID-19 in pregnancy, we applied liver protective and antiviral agents, and low-dose dexamethasone therapy to successfully treat the critically ill pregnant woman suffering from chronic active hepatitis B combined with COVID-19." provenance.
- SENTENCE label "In a case of chronic active hepatitis B with COVID-19 in pregnancy, we applied liver protective and antiviral agents, and low-dose dexamethasone therapy to successfully treat the critically ill pregnant woman suffering from chronic active hepatitis B combined with COVID-19." provenance.
- SENTENCE label "In a case of chronic active hepatitis B with COVID-19 in pregnancy, we applied liver protective and antiviral agents, and low-dose dexamethasone therapy to successfully treat the critically ill pregnant woman suffering from chronic active hepatitis B combined with COVID-19." provenance.
- SENTENCE label "In a case of chronic active hepatitis B with COVID-19 in pregnancy, we applied liver protective and antiviral agents, and low-dose dexamethasone therapy to successfully treat the critically ill pregnant woman suffering from chronic active hepatitis B combined with COVID-19." provenance.
- SENTENCE label "In a case of chronic active hepatitis B with COVID-19 in pregnancy, we applied liver protective and antiviral agents, and low-dose dexamethasone therapy to successfully treat the critically ill pregnant woman suffering from chronic active hepatitis B combined with COVID-19." provenance.
- SENTENCE label "In a case of chronic active hepatitis B with COVID-19 in pregnancy, we applied liver protective and antiviral agents, and low-dose dexamethasone therapy to successfully treat the critically ill pregnant woman suffering from chronic active hepatitis B combined with COVID-19." provenance.
- SENTENCE label "In a case of chronic active hepatitis B with COVID-19 in pregnancy, we applied liver protective and antiviral agents, and low-dose dexamethasone therapy to successfully treat the critically ill pregnant woman suffering from chronic active hepatitis B combined with COVID-19." provenance.
- SENTENCE label "In a case of chronic active hepatitis B with COVID-19 in pregnancy, we applied liver protective and antiviral agents, and low-dose dexamethasone therapy to successfully treat the critically ill pregnant woman suffering from chronic active hepatitis B combined with COVID-19." provenance.
- SENTENCE label "In a case of chronic active hepatitis B with COVID-19 in pregnancy, we applied liver protective and antiviral agents, and low-dose dexamethasone therapy to successfully treat the critically ill pregnant woman suffering from chronic active hepatitis B combined with COVID-19." provenance.
- SENTENCE label "In a case of chronic active hepatitis B with COVID-19 in pregnancy, we applied liver protective and antiviral agents, and low-dose dexamethasone therapy to successfully treat the critically ill pregnant woman suffering from chronic active hepatitis B combined with COVID-19." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.